IBS Capital Allies

Founder and CEO Hans van Ierland leads investment decisions. He established the firm in 2009 and maintains a concentrated portfolio approach, typically holding fewer than 15 positions at any time. Van Ierland's prior background includes institutional asset management roles in Amsterdam before launching the family-backed vehicle.

IBS Capital Allies operates as a single-family office managing capital for one European ultra-high-net-worth family, but its investment approach mimics a direct institutional growth manager. The firm makes direct equity investments in private technology companies rather than functioning as an allocator to external funds. This hybrid posture distinguishes IBS from most European family offices, which tend to access private markets through fund commitments.

IBS targets later-stage venture and growth equity rounds, typically Series C and beyond. The firm writes direct equity checks of $20 million or more, often participating alongside large multi-stage venture and growth firms. The concentrated portfolio means IBS typically holds fewer than 15 active positions across both private and public markets.

IBS Capital Allies focuses almost exclusively on direct investments, both in private growth-stage companies and in public equities. The firm does not market itself as a fund-of-funds allocator and has historically preferred writing equity checks directly into companies alongside co-investors like Insight Partners and General Atlantic.

IBS has not publicly disclosed an exclusion list, but its disclosed investment activity concentrates heavily on enterprise software, fintech, and digital health. The firm does not appear to invest in hardware-heavy deep tech, bio-pharma, or early-stage pre-revenue startups, based on its stated preference for later-stage, revenue-generating technology companies. Sectors such as fossil fuel extraction and heavy manufacturing are absent from the known portfolio, consistent with the firm's technology focus.

IBS sources opportunities primarily through the syndicate relationships it has built with large multi-stage growth investors, including Insight Partners and General Atlantic. The Amsterdam location gives IBS proximity to the broader European fintech and enterprise software ecosystem. The firm's willingness to write meaningful checks into later-stage rounds, combined with the discretion of a single-family anchor, provides an edge in co-investor invitations.

IBS Capital Allies participated in wefox's Series E funding round in July 2023, joining existing backers Omers Ventures and Gsquared (per Bloomberg, July 2023). The investment fits IBS's pattern of deploying into later-stage European insurtech alongside established growth-stage institutional investors.